Taking a Holiday From Osteoporosis Medication: What Do the Guidelines Actually Recommend?

If you've been on a bisphosphonate (like Fosamax, Binosto, Actonel, Boniva, or Reclast) for osteoporosis for several years, your doctor may have mentioned something called a "drug holiday"—a planned, temporary pause in treatment. It's a real, guideline-supported strategy, but it's also one of the more nuanced decisions in bone health, and I want to walk through the actual risk-benefit tradeoff rather than a blanket yes or no.

Why a holiday is even on the table

Bisphosphonates work differently than most medications you take. They bind directly to bone and release slowly over years, which means their protective effect doesn't disappear the moment you stop taking them—unlike denosumab, where stopping triggers rapid rebound bone loss and a real risk of multiple vertebral fractures. This is an important distinction: A holiday is a bisphosphonate-specific strategy. If you're on denosumab, stopping without transitioning to another agent is not the same low-risk pause, and it's not something guidelines recommend.

The reason a holiday exists at all is a genuine tradeoff. The longer you stay on a bisphosphonate, the more your risk rises for two rare but serious complications: atypical femoral fracture and osteonecrosis of the jaw. In one large cohort of over 196,000 women, that atypical fracture risk climbed the longer treatment continued, and one major study found the risk dropped by more than 80% within three years of stopping. That's a meaningful enough signal that guidelines take it seriously.

What you actually give up by pausing

Here's the part I think deserves the clearest explanation. Two major extension trials looked at exactly this question. In the FLEX trial, women who stopped alendronate (Fosamax or Binosto) after five years, instead of continuing to ten, had more clinical vertebral fractures, 5.3% versus 2.4%, though no difference in hip or other nonvertebral fractures. The HORIZON extension trial found something similar with zoledronate (Reclast): more new vertebral fractures after stopping at three years instead of six, again with no difference in hip fracture risk. So the honest summary is this: Continuing longer mainly protects against vertebral fractures specifically, not hip or other fractures. That's a real, quantifiable tradeoff, not a guess.

Who's actually a good candidate

This is genuinely individualized, and it depends heavily on your personal fracture risk.

If you're at low-to-moderate risk after five years of oral therapy or three years of IV therapy—meaning your bone density T-score is better than negative 2.5 and you haven't fractured while on treatment—a holiday is generally appropriate.

If you're at high risk—meaning a T-score at or below negative 2.5, a prior fracture, or a high FRAX score—guidelines generally favor continuing to 10 years oral or six years IV, or switching strategies entirely, rather than pausing.

A detail rarely mentioned: This isn't one-size-fits-all across populations

One analysis published in the New England Journal of Medicine found that the calculation shifts by ancestry. In White women, fractures prevented by continued treatment vastly outnumbered atypical fractures at every duration studied. In Asian women, that margin narrowed considerably by the 10-year mark, suggesting shorter treatment courses and earlier holidays may make more sense for that group specifically. This is exactly the kind of nuance that gets lost in generic guidance.

A holiday isn't a permanent decision

The Endocrine Society recommends reassessing your fracture risk every two to four years during a holiday, and resuming sooner than the typical five-year mark if your bone density drops meaningfully, you experience a new fracture, or your risk profile changes. Fracture rates generally don't rise in the first year or two of the holiday, but the risk can climb between years two and five, which is exactly why this needs to stay a monitored decision, not a "set it and forget it" one.

The honest bottom line: This is a real, guideline-endorsed option for the right person, built on a genuine tradeoff between rare drug-related risks and vertebral fracture protection. And it deserves a specific conversation with your doctor about your own bone density, fracture history, and risk profile—not a one-size-fits-all rule.